C4X Discovery announce ‘sizeable deal and one we’re very proud of’ with Sanofi worth up to €414mln

Clive Dix talks Proactive London’s Katie Pilbeam about their worldwide licensing deal with international drugs giant Sanofi worth up to €414mln.

The group will receive €7mln upfront, plus €11mln in pre-clinical payments.

The deal is for their oral IL-17A inhibitor programme, currently IL-17 monoclonal antibodies are administered by injection. Having an oral version represents a significant breakthrough.